ChiCTR2000039708 版本V1.3 版本创建时间2021/02/11 00:37:25 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000039708 

最近更新日期:

Date of Last Refreshed on:

2021-02-11 00:23:07 

注册时间:

Date of Registration:

2020-11-06 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

重症患者中心静脉烟雾样超声显影与血栓弹力图检查结果相关性研究

Public title:

Prospective study on the relationship between the results of thromboelastogram and entral venous smoke-like echo in critically ill patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

重症患者中心静脉烟雾样超声显影与血栓弹力图检查结果相关性研究

Scientific title:

Prospective study on the relationship between the results of thromboelastogram and entral venous smoke-like echo in critically ill patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王庆宇 

研究负责人:

王庆宇 

Applicant:

Qingyu Wang 

Study leader:

Qingyu Wang 

申请注册联系人电话:

Applicant telephone:

+86 15858381681

研究负责人电话:

Study leader's telephone:

+86 15858381681

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

45661849@qq.com

研究负责人电子邮件:

Study leader's E-mail:

45661849@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省嘉兴市环城北路1518号嘉兴学院附属第二医院嘉兴市第二医院ICU

研究负责人通讯地址:

浙江省嘉兴市环城北路1518号嘉兴学院附属第二医院嘉兴市第二医院ICU

Applicant address:

ICU of the Second Affiliated Hospital of Jiaxing University, 1518 Ring Road North, Jiaxing, Zhejiang, China

Study leader's address:

ICU of the Second Affiliated Hospital of Jiaxing University, 1518 Ring Road North, Jiaxing, Zhejiang, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

嘉兴市第二医院

Applicant's institution:

Jiaxing Second Hospital

研究负责人所在单位:

嘉兴市第二医院

Affiliation of the Leader:

Jiaxing Second Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

JXEY-2020JX052

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

嘉兴市第二医院伦理委员会

Name of the ethic committee:

The Medical Ethics Committee of Jiaxing Second Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2019-11-27 00:00:00

伦理委员会联系人:

谢建英

Contact Name of the ethic committee:

Jianying Xie

伦理委员会联系地址:

浙江省嘉兴市环城北路1518号嘉兴学院附属第二医院嘉兴市第二医院ICU

Contact Address of the ethic committee:

ICU of the Second Affiliated Hospital of Jiaxing University, 1518 Ring Road North, Jiaxing, Zhejiang, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 573-82050475

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

嘉兴市第二医院

Primary sponsor:

Jiaxing Second Hospital

研究实施负责(组长)单位地址:

浙江省嘉兴市环城北路1518号嘉兴学院附属第二医院嘉兴市第二医院ICU

Primary sponsor's address:

ICU of the Second Affiliated Hospital of Jiaxing University, 1518 Ring Road North, Jiaxing, Zhejiang, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

嘉兴

Country:

China

Province:

Zhejiang

City:

Jiaxing

单位(医院):

嘉兴市第二医院

具体地址:

环城北路1518号嘉兴学院附属第二医院嘉兴市第二医院ICU

Institution
hospital:

Jiaxing Second Hospital

Address:

ICU of the Second Affiliated Hospital of Jiaxing University, 1518 Ring Road North

经费或物资来源:

浙江省嘉兴市科技计划资助项目

Source(s) of funding:

Jiaxing city, Zhejiang province science and technology plan projects

Target disease:

Deep vein thrombosis

Target disease code:

研究类型:

病因学/相关因素研究

Study type:

Cause/Relative factors study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

明确重症患者中心静脉烟雾样超声显影与血栓弹力图检查结果相关性。  

Objectives of Study:

To determine the correlation between thromboelastography and smog like echo of cardiac vein in critical patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1、新入ICU的重症患者,男女不限;
2、年龄≥18岁;
3、每位患者入组前征得患方同意并签署知情同意书。

Inclusion criteria

1. New ICU patients with severe illness, male and female
2. Patients aged 18 years or above;
3. The informed consent was obtained and signed by each patient before admission.

排除标准:

近一周内有使用抗凝或抗血小板药物或接受溶栓治疗。

Exclusion criteria:

The patients who used anticoagulant or antiplatelet drugs or received thrombolytic therapy in the past week.

研究实施时间:

Study execute time:

From 2020-07-01 00:00:00 To 2022-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-12-01 00:00:00 To 2022-06-30 00:00:00  

干预措施:

Interventions:

组别:

case series

样本量:

300

Group:

case series

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

组别:

case series

样本量:

300

Group:

case series

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

嘉兴 

Country:

China 

Province:

Zhejiang 

City:

Jiaxing 

单位(医院):

嘉兴市第二医院 

单位级别:

三级甲等 

Institution
hospital:

Jiaxing Second Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

烟雾样血流

指标类型:

主要指标

Outcome:

SECSpontaneous echo contrast

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

凝血反应时间

指标类型:

主要指标

Outcome:

R

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血液凝固时间

指标类型:

主要指标

Outcome:

K

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

两侧曲线的最宽距离

指标类型:

主要指标

Outcome:

MA

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

α角

指标类型:

主要指标

Outcome:

α-Angle

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血块溶解百分比

指标类型:

主要指标

Outcome:

Estimate Percent Lysis (EPL)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

30分钟血块减少幅度速率

指标类型:

主要指标

Outcome:

LY30

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

凝血综合指数

指标类型:

主要指标

Outcome:

Coagulation index (CI)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血浆凝血酶原时间

指标类型:

次要指标

Outcome:

PT

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

活化部分凝血活酶时间

指标类型:

次要指标

Outcome:

APTT

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

的国际标准化比值

指标类型:

次要指标

Outcome:

INR

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血浆纤维蛋白原

指标类型:

次要指标

Outcome:

Fbg

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

D二聚体

指标类型:

次要指标

Outcome:

DDi

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 100 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

通过中国临床试验注册中心公布数据,网址:http://www.chictr.org.cn/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Data released through China clinical trial registry http://www.chictr.org.cn/

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集由本人及研究小组内成员采集,记录到病例记录表中,定期(每周)由专人录入中国临床试验注册中心的ResMan系统。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection is collected by myself and members of the research team, recorded in the case record form, and regularly (weekly) entered into the ResMan system of the China Clinical Trial Registration Center.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-11-06 01:02:32